Jagsonpal Acquires Wellness Portfolio & Euphoria Wins Contract

Jagsonpal Pharmaceuticals shares rose 7.15%, gaining 16.15 points to trade at Rs. 242.05 on the BSE from a previous close of Rs. 225.90. Simultaneously, corporate developments show that Euphoria Infotech has secured a new work order valued at Rs. 4.03 crore.

Trading Metrics and Contract Details

Trading activity on the Jagsonpal counter recorded a volume of 221316 shares following an open at Rs. 230.05. Meanwhile, the work order secured by Euphoria Infotech is scheduled for completion within a seven-month timeframe.

• High: Rs. 247.00
• Low: Rs. 230.05
• Market Cap: Rs. 1600.79 crore
• Promoter Holding: 69.05%

The group ‘B’ stock of face value Rs. 2 reached a 52-week high of Rs. 264.65 on 30-Jun-2026 and a 52-week low of Rs. 154.90 on 22-Jan-2026. Last one week high and low of the scrip stood at Rs. 247.00 and Rs. 222.45 respectively.

Acquisition Information

Jagsonpal Pharmaceuticals has executed a Business Transfer Agreement with Group Pharmaceuticals for the acquisition of Group Pharma’s Wellness Portfolio on a going-concern basis by way of slump sale. The transaction brings in an established portfolio of products and an existing market presence.

• Completion Date: November 1, 2026
• Institution Holding: 2.92%
• Non-Institution Holding: 28.03%

The company intends to integrate this business with its existing commercial platform and capabilities while leveraging its existing distribution network to create operating synergies. Jagsonpal Pharmaceuticals is among India’s premiere pharmaceutical companies, maintaining substantial research and development, manufacturing, marketing, and distribution facilities.